| scholarly article | Q13442814 |
| P50 | author | Soo Han Bae | Q63610172 |
| P2093 | author name string | Sung Won Kwon | |
| Dong-Kyu Lee | |||
| Byung-Wan Lee | |||
| Jeong Su Park | |||
| Da Hyun Lee | |||
| Yu Seol Lee | |||
| P2860 | cites work | mTOR signaling in growth control and disease | Q24634174 |
| AKT/PKB signaling: navigating downstream | Q24657857 | ||
| The Natural Course of Non-Alcoholic Fatty Liver Disease | Q26746947 | ||
| Transcriptional regulation of hepatic lipogenesis | Q26778594 | ||
| Sestrins activate Nrf2 by promoting p62-dependent autophagic degradation of Keap1 and prevent oxidative liver damage | Q28117084 | ||
| Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways | Q28242180 | ||
| Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c | Q28297047 | ||
| Comprehensive analysis of lipids in biological systems by liquid chromatography-mass spectrometry | Q28395402 | ||
| Regulation of hepatic lipogenesis by the transcription factor XBP1 | Q28507784 | ||
| PERK-dependent activation of Nrf2 contributes to redox homeostasis and cell survival following endoplasmic reticulum stress | Q28511471 | ||
| A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver | Q28583240 | ||
| SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver | Q29547646 | ||
| Activation of a metabolic gene regulatory network downstream of mTOR complex 1 | Q29615179 | ||
| Molecular mediators of hepatic steatosis and liver injury | Q29616709 | ||
| The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association | Q29617157 | ||
| mTOR signaling at a glance | Q29619857 | ||
| mTOR complex 1 regulates lipin 1 localization to control the SREBP pathway | Q30425628 | ||
| Nonalcoholic Fatty Liver Disease and Insulin Resistance: New Insights and Potential New Treatments | Q33616887 | ||
| mTORC1 activates SREBP-1c and uncouples lipogenesis from gluconeogenesis. | Q33734395 | ||
| Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis | Q33734679 | ||
| Non-alcoholic fatty liver disease: An expanded review | Q33789868 | ||
| Akt-dependent activation of mTORC1 complex involves phosphorylation of mTOR (mammalian target of rapamycin) by IκB kinase α (IKKα). | Q34139142 | ||
| Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. | Q34315432 | ||
| Herbal formulation, DIA-2 and Rosiglitazone ameliorates hyperglycemia and hepatic steatosis in type 2 diabetic rats. | Q50561554 | ||
| Carcinogenicity study of CKD-501, a novel dual peroxisome proliferator-activated receptors α and γ agonist, following oral administration to Sprague Dawley rats for 94-101 weeks. | Q53056780 | ||
| Safety and efficacy of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 52 weeks: An open-label extension study. | Q53191415 | ||
| Astaxanthin reduces hepatic lipid accumulations in high-fat-fed C57BL/6J mice via activation of peroxisome proliferator-activated receptor (PPAR) alpha and inhibition of PPAR gamma and Akt. | Q55030805 | ||
| Treatment with Lobeglitazone Attenuates Hepatic Steatosis in Diet-Induced Obese Mice. | Q55691519 | ||
| Role for PPARγ in obesity-induced hepatic steatosis as determined by hepatocyte- and macrophage-specific conditional knockouts | Q61575260 | ||
| The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance | Q74453774 | ||
| Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement | Q79825065 | ||
| Hepatocyte-specific Pten-deficient mice as a novel model for nonalcoholic steatohepatitis and hepatocellular carcinoma | Q81329832 | ||
| Lipid metabolism and liver inflammation. II. Fatty liver disease and fatty acid oxidation | Q34512108 | ||
| Quantification of CKD-501, lobeglitazone, in rat plasma using a liquid-chromatography/tandem mass spectrometry method and its applications to pharmacokinetic studies | Q34990638 | ||
| Insulin stimulation of SREBP-1c processing in transgenic rat hepatocytes requires p70 S6-kinase | Q36342908 | ||
| De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose | Q36800168 | ||
| Pioglitazone stimulates AMP-activated protein kinase signalling and increases the expression of genes involved in adiponectin signalling, mitochondrial function and fat oxidation in human skeletal muscle in vivo: a randomised trial | Q36972810 | ||
| Rosiglitazone is associated with mortality in chronic hemodialysis patients. | Q37181975 | ||
| Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension | Q37257466 | ||
| Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). | Q37281827 | ||
| Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. | Q37388544 | ||
| Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness | Q37482466 | ||
| As a matter of fat. | Q37543677 | ||
| In vivo actions of peroxisome proliferator-activated receptors: glycemic control, insulin sensitivity, and insulin secretion | Q37577126 | ||
| Clinical approaches to non-alcoholic fatty liver disease | Q37596187 | ||
| Thiazolidinediones and PPARγ agonists: time for a reassessment | Q38003533 | ||
| New insights into ER stress-induced insulin resistance. | Q38024445 | ||
| A Central role for mTOR in lipid homeostasis | Q38131225 | ||
| PPARgamma2 regulates lipogenesis and lipid accumulation in steatotic hepatocytes. | Q38332175 | ||
| Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression | Q38361574 | ||
| CKD-501, a novel selective PPARγ agonist, shows no carcinogenic potential in ICR mice following oral administration for 104 weeks | Q38446975 | ||
| Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies | Q38705659 | ||
| Endoplasmic reticulum proteostasis in hepatic steatosis. | Q38925531 | ||
| Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis. | Q39097575 | ||
| Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model | Q39165020 | ||
| Role of peroxisome proliferator-activated receptor gamma agonist in improving hepatic steatosis: Possible molecular mechanism | Q39604886 | ||
| Dephosphorylation of translation initiation factor 2alpha enhances glucose tolerance and attenuates hepatosteatosis in mice | Q39975807 | ||
| A futile metabolic cycle activated in adipocytes by antidiabetic agents | Q40700524 | ||
| Mammalian mitochondrial beta-oxidation | Q41280085 | ||
| Update on pparγ and nonalcoholic Fatty liver disease | Q41903480 | ||
| Preparation of fatty acid methyl esters for gas-liquid chromatography | Q42062849 | ||
| Isolation and primary culture of rat hepatic cells | Q42175713 | ||
| A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis | Q44749300 | ||
| Metabolic characterization of hepatocellular carcinoma using nontargeted tissue metabolomics | Q44819530 | ||
| Pioglitazone and risk of bladder cancer: clarification of the design of the French study. Reply to Perez AT [letter]. | Q46868396 | ||
| Structures of PPARγ complexed with lobeglitazone and pioglitazone reveal key determinants for the recognition of antidiabetic drugs | Q47169300 | ||
| Current and future pharmacological therapies for NAFLD/NASH. | Q47778507 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sirolimus | Q32089 |
| P304 | page(s) | 539 | |
| P577 | publication date | 2018-09-21 | |
| P1433 | published in | Frontiers in Endocrinology | Q27723680 |
| P1476 | title | The Antidiabetic Drug Lobeglitazone Protects Mice From Lipogenesis-Induced Liver Injury via Mechanistic Target of Rapamycin Complex 1 Inhibition | |
| P478 | volume | 9 |
Search more.